<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?>
<document xmlns:voc="http://www.hl7.org/v3/voc" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
	<id root="CF9BC855-99A4-D3CC-A903-D0B104DC7075"/>
	<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING"/>
	<title mediaType="text/x-hl7-title+xml">
		<content styleCode="bold">CAPTOPRIL AND HYDROCHLOROTHIAZIDE<br/>TABLETS, USP</content>
	</title>
	<effectiveTime value="20060216"/>
	<setId root="0B49725D-6FE6-4D11-BA80-D622FDC054EC"/>
	<versionNumber value="1"/>
	<author>
  <time/>
  <assignedEntity>
   <representedOrganization>
    <name>Endo Pharmaceuticals Inc.</name>
   </representedOrganization>
  </assignedEntity>
</author>
	<component>
		<structuredBody>
			<component>
				<section>
					<id root="07B3B07B-5DBA-28C3-A99D-8A4BE1C360CA"/>
					<effectiveTime value="20060216"/>
					<subject>
						<manufacturedProduct>
							<manufacturedMedicine>
								<code code="60951-733" codeSystem="2.16.840.1.113883.6.69"/>
								<name>Captopril and Hydrochlorothiazide</name>
								<formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
								<activeIngredient>
									<quantity>
										<numerator unit="mg" value="25">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="25"/>
										</numerator>
										<denominator value="1">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="9G64RSX1XD" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>Captopril</name>
										<activeMoiety>
											<activeMoiety>
												<code code="9G64RSX1XD" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>Captopril</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<activeIngredient>
									<quantity>
										<numerator unit="mg" value="15">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="15"/>
										</numerator>
										<denominator value="1">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="0J48LPH2TH" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>Hydrochlorothiazide</name>
										<activeMoiety>
											<activeMoiety>
												<code code="0J48LPH2TH" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>Hydrochlorothiazide</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<asEntityWithGeneric>
									<genericMedicine>
										<name>Captopril and Hydrochlorothiazide</name>
									</genericMedicine>
								</asEntityWithGeneric>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>lactose monohydrate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>magnesium stearate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>microcrystalline cellulose</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>pregelatinized starch</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>stearic acid</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<asContent>
									<quantity>
										<numerator value="100">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100"/>
										</numerator>
										<denominator value="1">
											<translation value="1"/>
										</denominator>
									</quantity>
									<containerPackagedMedicine>
										<code code="60951-733-70" codeSystem="2.16.840.1.113883.6.69"/>
										<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
									</containerPackagedMedicine>
								</asContent>
							</manufacturedMedicine>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
										<originalText>WHITE</originalText>
									</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
										<originalText>ROUND</originalText>
									</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="true" xsi:type="BL"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="false" xsi:type="BL"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value unit="mm" value="8" xsi:type="PQ"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="4" xsi:type="INT"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value xsi:type="ST">Endo;733</value>
								</characteristic>
							</subjectOf>
							<consumedIn>
								<substanceAdministration>
									<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
								</substanceAdministration>
							</consumedIn>
						</manufacturedProduct>
					</subject>
					<subject>
						<manufacturedProduct>
							<manufacturedMedicine>
								<code code="60951-741" codeSystem="2.16.840.1.113883.6.69"/>
								<name>Captopril and Hydrochlorothiazide</name>
								<formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
								<activeIngredient>
									<quantity>
										<numerator unit="mg" value="25">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="25"/>
										</numerator>
										<denominator value="1">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="9G64RSX1XD" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>Captopril</name>
										<activeMoiety>
											<activeMoiety>
												<code code="9G64RSX1XD" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>Captopril</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<activeIngredient>
									<quantity>
										<numerator unit="mg" value="25">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="25"/>
										</numerator>
										<denominator value="1">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="0J48LPH2TH" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>Hydrochlorothiazide</name>
										<activeMoiety>
											<activeMoiety>
												<code code="0J48LPH2TH" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>Hydrochlorothiazide</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<asEntityWithGeneric>
									<genericMedicine>
										<name>Captopril and Hydrochlorothiazide</name>
									</genericMedicine>
								</asEntityWithGeneric>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>lactose monohydrate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>magnesium stearate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>microcrystalline cellulose</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>pregelatinized starch</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>stearic acid</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<asContent>
									<quantity>
										<numerator value="100">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100"/>
										</numerator>
										<denominator value="1">
											<translation value="1"/>
										</denominator>
									</quantity>
									<containerPackagedMedicine>
										<code code="60951-741-70" codeSystem="2.16.840.1.113883.6.69"/>
										<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
									</containerPackagedMedicine>
								</asContent>
							</manufacturedMedicine>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value code="C48331" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORANGE" xsi:type="CE">
										<originalText>ORANGE</originalText>
									</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
										<originalText>ROUND</originalText>
									</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="true" xsi:type="BL"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="false" xsi:type="BL"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value unit="mm" value="8" xsi:type="PQ"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="4" xsi:type="INT"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value xsi:type="ST">Endo;741</value>
								</characteristic>
							</subjectOf>
							<consumedIn>
								<substanceAdministration>
									<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
								</substanceAdministration>
							</consumedIn>
						</manufacturedProduct>
					</subject>
					<subject>
						<manufacturedProduct>
							<manufacturedMedicine>
								<code code="60951-739" codeSystem="2.16.840.1.113883.6.69"/>
								<name>Captopril and Hydrochlorothiazide</name>
								<formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
								<activeIngredient>
									<quantity>
										<numerator unit="mg" value="50">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="50"/>
										</numerator>
										<denominator value="1">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="9G64RSX1XD" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>Captopril</name>
										<activeMoiety>
											<activeMoiety>
												<code code="9G64RSX1XD" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>Captopril</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<activeIngredient>
									<quantity>
										<numerator unit="mg" value="15">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="15"/>
										</numerator>
										<denominator value="1">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="0J48LPH2TH" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>Hydrochlorothiazide</name>
										<activeMoiety>
											<activeMoiety>
												<code code="0J48LPH2TH" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>Hydrochlorothiazide</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<asEntityWithGeneric>
									<genericMedicine>
										<name>Captopril and Hydrochlorothiazide</name>
									</genericMedicine>
								</asEntityWithGeneric>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>lactose monohydrate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>magnesium stearate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>microcrystalline cellulose</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>pregelatinized starch</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>stearic acid</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<asContent>
									<quantity>
										<numerator value="100">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100"/>
										</numerator>
										<denominator value="1">
											<translation value="1"/>
										</denominator>
									</quantity>
									<containerPackagedMedicine>
										<code code="60951-739-70" codeSystem="2.16.840.1.113883.6.69"/>
										<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
									</containerPackagedMedicine>
								</asContent>
							</manufacturedMedicine>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
										<originalText>WHITE</originalText>
									</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
										<originalText>ROUND</originalText>
									</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="true" xsi:type="BL"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="false" xsi:type="BL"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value unit="mm" value="9" xsi:type="PQ"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="2" xsi:type="INT"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value xsi:type="ST">Endo;739</value>
								</characteristic>
							</subjectOf>
							<consumedIn>
								<substanceAdministration>
									<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
								</substanceAdministration>
							</consumedIn>
						</manufacturedProduct>
					</subject>
					<subject>
						<manufacturedProduct>
							<manufacturedMedicine>
								<code code="60951-731" codeSystem="2.16.840.1.113883.6.69"/>
								<name>Captopril and Hydrochlorothiazide</name>
								<formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
								<activeIngredient>
									<quantity>
										<numerator unit="mg" value="50">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="50"/>
										</numerator>
										<denominator value="1">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="9G64RSX1XD" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>Captopril</name>
										<activeMoiety>
											<activeMoiety>
												<code code="9G64RSX1XD" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>Captopril</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<activeIngredient>
									<quantity>
										<numerator unit="mg" value="25">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="25"/>
										</numerator>
										<denominator value="1">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="0J48LPH2TH" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>Hydrochlorothiazide</name>
										<activeMoiety>
											<activeMoiety>
												<code code="0J48LPH2TH" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>Hydrochlorothiazide</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<asEntityWithGeneric>
									<genericMedicine>
										<name>Captopril and Hydrochlorothiazide</name>
									</genericMedicine>
								</asEntityWithGeneric>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>lactose monohydrate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>magnesium stearate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>microcrystalline cellulose</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>pregelatinized starch</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>stearic acid</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<asContent>
									<quantity>
										<numerator value="100">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100"/>
										</numerator>
										<denominator value="1">
											<translation value="1"/>
										</denominator>
									</quantity>
									<containerPackagedMedicine>
										<code code="60951-731-70" codeSystem="2.16.840.1.113883.6.69"/>
										<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
									</containerPackagedMedicine>
								</asContent>
							</manufacturedMedicine>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value code="C48331" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORANGE" xsi:type="CE">
										<originalText>ORANGE</originalText>
									</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
										<originalText>ROUND</originalText>
									</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="true" xsi:type="BL"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="false" xsi:type="BL"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value unit="mm" value="9" xsi:type="PQ"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="2" xsi:type="INT"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value xsi:type="ST">Endo;731</value>
								</characteristic>
							</subjectOf>
							<consumedIn>
								<substanceAdministration>
									<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
								</substanceAdministration>
							</consumedIn>
						</manufacturedProduct>
					</subject>
				</section>
			</component>
			<component>
				<section ID="SD736C2BB-A38C-4975-A1E3-BD1F0EC9CAC8">
					<id root="33F9A483-CA3C-5C08-E758-AA9DD35028E6"/>
					<code code="34066-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="BOXED WARNING SECTION"/>
					<text>
						<paragraph>
							<content styleCode="bold">USE IN PREGNANCY</content>
							<br/>
							<content styleCode="bold">When used in pregnancy during the second
                                and third trimesters, ACE inhibitors can cause injury and even death
                                to the developing fetus. </content>When pregnancy is detected,        Captopril and Hydrochlorothiazide should be discontinued as soon as
                            possible. <content styleCode="bold">See <linkHtml href="#SCC1D9261-A090-4EED-9B40-B8882FBEDA01">WARNINGS:
                                    Captopril, Fetal/Neonatal Morbidity and
                            Mortality</linkHtml>.</content>
						</paragraph>
					</text>
					<effectiveTime value="20060216"/>
				</section>
			</component>
			<component>
				<section ID="S606D0CEC-6027-49F1-9181-222E90D339D5">
					<id root="128A2758-A197-D0CF-15AB-9B1C31D736BB"/>
					<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION"/>
					<title mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
					<text>
						<paragraph>Captopril and hydrochlorothiazide are two oral antihypertensive
                            agents. Captopril, the first of a new class of antihypertensive agents,
                            is a specific competitive inhibitor of angiotensin I-converting enzyme
                            (ACE), the enzyme responsible for the conversion of angiotensin I to
                            angiotensin II. Hydrochlorothiazide is a benzothiadiazide (thiazide)
                            diuretic-antihypertensive.</paragraph>
						<paragraph>Captopril is a white to off-white crystalline powder that may
                            have a slight sulfurous odor; it is soluble in water (approx. 160
                            mg/mL), methanol, and ethanol and sparingly soluble in chloroform and
                            ethyl acetate. </paragraph>
						<paragraph>Hydrochlorothiazide is a white crystalline powder slightly
                            soluble in water but freely soluble in sodium hydroxide solution.</paragraph>
						<paragraph>Captopril is designated chemically as                   1-[(2S)-3-Mercapto-2-methylpropionyl]-L-proline; hydrochlorothiazide is
                                6-Chloro-3,4-dihydro-2<content styleCode="italics">H</content>-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Their
                            structural formulas are:</paragraph>
						<paragraph>
							<renderMultiMedia referencedObject="MM10"/>
						</paragraph>
						<paragraph>Each tablet, for oral administration, contains captopril and
                            hydrochlorothiazide, 25 mg/15 mg, 25 mg/25 mg, 50 mg/15 mg, or 50 mg/25                          mg. In addition, each tablet contains the following inactive
                            ingredients: lactose monohydrate, magnesium stearate, microcrystalline
                            cellulose, pregelatinized starch and stearic acid. In addition, colorant
                            (FD&amp;C Yellow No. 6) is contained in the 25 mg/25 mg and 50 mg/25
                            mg tablets.</paragraph>
					</text>
					<effectiveTime value="20060216"/>
					<component>
						<observationMedia ID="MM10">
							<value mediaType="image/jpg" xsi:type="ED">
								<reference value="captopril-and-hydrochlorothiazide-figure-1.jpg"/>
							</value>
						</observationMedia>
					</component>
				</section>
			</component>
			<component>
				<section ID="SCCC5CBEB-854C-43E0-BCC8-DC43163F71D5">
					<id root="EC6E6352-D059-65AC-F9F5-294E9B2EA6E8"/>
					<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL PHARMACOLOGY"/>
					<title mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
					<effectiveTime value="20060216"/>
					<component>
						<section ID="SC6385103-0859-4CD9-B66E-3A5590C430FB">
							<id root="5381761F-BA87-FBE8-517B-6F70D88A44CF"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
							<title mediaType="text/x-hl7-title+xml">Captopril</title>
							<effectiveTime value="20060216"/>
							<component>
								<section ID="S1A01E63A-D99C-4FCA-A165-8592559B78A7">
									<id root="9A200422-7BF2-35DF-4BBC-7988230C28E7"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Mechanism of Action</title>
									<text>
										<paragraph>The mechanism of action of captopril has not yet
                                            been fully elucidated. Its beneficial effects in
                                            hypertension and heart failure appear to result
                                            primarily from suppression of the
                                            renin-angiotensin-aldosterone system. However, there is
                                            no consistent correlation between renin levels and
                                            response to the drug. Renin, an enzyme synthesized by
                                            the kidneys, is released into the circulation where it
                                            acts on a plasma globulin substrate to produce
                                            angiotensin I, a relatively inactive decapeptide.
                                            Angiotensin I is then converted by angiotensin
                                            converting enzyme (ACE) to angiotensin II, a potent
                                            endogenous vasoconstrictor substance. Angiotensin II
                                            also stimulates aldosterone secretion from the adrenal
                                            cortex, thereby contributing to sodium and fluid
                                            retention. </paragraph>
										<paragraph>Captopril prevents the conversion of angiotensin
                                            I to angiotensin II by inhibition of ACE, a
                                            peptidyldipeptide carboxy hydrolase. This inhibition has
                                            been demonstrated in both healthy human subjects and in
                                            animals by showing that the elevation of blood pressure
                                            caused by exogenously administered angiotensin I was
                                            attenuated or abolished by captopril. In animal studies,
                                            captopril did not alter the pressor responses to a
                                            number of other agents, including angiotensin II and
                                            norepinephrine, indicating specificity of action.</paragraph>
										<paragraph>ACE is identical to&#8220;bradykininase&#8221;, and captopril may
                                            also interfere with the degradation of the vasodepressor
                                            peptide, bradykinin. Increased concentrations of
                                            bradykinin or prostaglandin E<sub>2</sub> may also have
                                            a role in the therapeutic effect of captopril.</paragraph>
										<paragraph>Inhibition of ACE results in decreased plasma
                                            angiotensin II and increased plasma renin activity
                                            (PRA), the latter resulting from loss of negative
                                            feedback on renin release caused by reduction in
                                            angiotensin II. The reduction of angiotensin II leads to
                                            decreased aldosterone secretion, and, as a result, small
                                            increases in serum potassium may occur along with sodium
                                            and fluid loss.</paragraph>
										<paragraph>The antihypertensive effects persist for a longer
                                            period of time than does demonstrable inhibition of
                                            circulating ACE. It is not known whether the ACE present
                                            in vascular endothelium is inhibited longer than the ACE
                                            in circulating blood.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S2DC53154-62DF-428F-B89A-A2C4566F5F43">
									<id root="49A47719-DE31-7A29-50E1-C517932A843A"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Pharmacokinetics</title>
									<text>
										<paragraph>After oral administration of therapeutic doses of
                                            captopril, rapid absorption occurs with peak blood
                                            levels at about one hour. The presence of food in the
                                            gastrointestinal tract reduces absorption by about 30 to                 40 percent; captopril therefore should be given one hour
                                            before meals. Based on carbon-14 labeling, average
                                            minimal absorption is approximately 75 percent. In a
                                            24-hour period, over 95 percent of the absorbed dose is
                                            eliminated in the urine; 40 to 50 percent is unchanged
                                            drug; most of the remainder is the disulfide dimer of
                                            captopril and captopril-cysteine disulfide.</paragraph>
										<paragraph>Approximately 25 to 30 percent of the circulating
                                            drug is bound to plasma proteins. The apparent
                                            elimination half-life for total radioactivity in blood
                                            is probably less than three hours. An accurate
                                            determination of half-life of unchanged captopril is
                                            not, at present, possible, but it is probably less than
                                            two hours. In patients with renal impairment, however,
                                            retention of captopril occurs (see <linkHtml href="#S752E7393-5D07-4A52-90E8-958DE89434A6">DOSAGE
                                                AND ADMINISTRATION</linkHtml>).</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S41098F9A-4269-43E9-9729-B5CDE540A5C8">
									<id root="3AA122DB-1F7B-8CAD-4DF0-B2D3A9AF8EE5"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Pharmacodynamics</title>
									<text>
										<paragraph>Administration of captopril results in a
                                            reduction of peripheral arterial resistance in
                                            hypertensive patients with either no change, or an
                                            increase, in cardiac output. There is an increase in
                                            renal blood flow following administration of captopril
                                            and glomerular filtration rate is usually unchanged. In
                                            patients with heart failure, significantly decreased
                                            peripheral (systemic vascular) resistance and blood
                                            pressure (afterload), reduced pulmonary capillary wedge
                                            pressure (preload) and pulmonary vascular resistance,
                                            increased cardiac output, and increased exercise
                                            tolerance time (ETT) have been demonstrated.</paragraph>
										<paragraph>Reductions of blood pressure are usually maximal
                                            60 to 90 minutes after oral administration of an
                                            individual dose of captopril. The duration of effect is             dose related and is extended in the presence of a
                                            thiazide-type diuretic. The full effect of a given dose
                                            may not be attained for 6 to 8 weeks (see <linkHtml href="#S752E7393-5D07-4A52-90E8-958DE89434A6">DOSAGE
                                                AND ADMINISTRATION</linkHtml>). The blood pressure
                                            lowering effects of captopril and thiazide-type
                                            diuretics are additive. In contrast, captopril and
                                            beta-blockers have a less than additive effect.</paragraph>
										<paragraph>Blood pressure is lowered to about the same
                                            extent in both standing and supine positions.
                                            Orthostatic effects and tachycardia are infrequent but
                                            may occur in volume-depleted patients. Abrupt withdrawal
                                            of captopril has not been associated with a rapid
                                            increase in blood pressure.</paragraph>
										<paragraph>Studies in rats and cats indicate that captopril
                                            does not cross the blood-brain barrier to any
                                            significant extent.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section ID="S7061AD21-70FE-4D9B-9220-81A5539C080D">
							<id root="B3948EE5-87C7-DEBF-3C29-284896803557"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
							<title mediaType="text/x-hl7-title+xml">Hydrochlorothiazide</title>
							<text>
								<paragraph>Thiazides affect the renal tubular mechanism of                electrolyte reabsorption. At maximal therapeutic dosage all
                                    thiazides are approximately equal in their diuretic potency. </paragraph>
								<paragraph>Thiazides increase excretion of sodium and chloride in
                                    approximately equivalent amounts. Natriuresis causes a secondary
                                    loss of potassium and bicarbonate.</paragraph>
								<paragraph>The mechanism of the antihypertensive effect of thiazides
                                    is unknown. Thiazides do not affect normal blood pressure.</paragraph>
								<paragraph>The mean plasma half-life of hydrochlorothiazide in
                                    fasted individuals has been reported to be approximately 2.5
                                    hours.</paragraph>
								<paragraph>Onset of diuresis occurs in two hours and the peak effect
                                    at about four hours. Its action persists for approximately six
                                    to twelve hours. Hydrochlorothiazide is eliminated rapidly by
                                    the kidney.</paragraph>
							</text>
							<effectiveTime value="20060216"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section ID="SD199C695-4AF1-440D-BC52-B22DC19DC3CB">
					<id root="6B493AA6-C9C9-9DEF-0E30-EE3D0E49312E"/>
					<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS &amp; USAGE"/>
					<title mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
					<text>
						<paragraph>Captopril and Hydrochlorothiazide tablets are indicated for the
                            treatment of hypertension. The blood pressure lowering effects of
                            captopril and thiazides are approximately additive. </paragraph>
						<paragraph>This fixed combination drug may be used as initial therapy or
                            substituted for previously titrated doses of the individual components.</paragraph>
						<paragraph>When captopril and hydrochlorothiazide are given together it may
                            not be necessary to administer captopril in divided doses to attain
                            blood pressure control at trough (before the next dose). Also, with such
                            a combination, a daily dose of 15 mg of hydrochlorothiazide may be
                            adequate.</paragraph>
						<paragraph>Treatment may, therefore, be initiated with Captopril and
                            Hydrochlorothiazide tablets 25 mg/15 mg once daily. Subsequent titration
                            should be with additional doses of the components (captopril,
                            hydrochlorothiazide) as single agents or as Captopril and
                            Hydrochlorothiazide tablets 50 mg/15 mg, 25 mg/25 mg, or 50 mg/25 mg
                            (see <linkHtml href="#S752E7393-5D07-4A52-90E8-958DE89434A6">DOSAGE AND
                                ADMINISTRATION</linkHtml>).</paragraph>
						<paragraph>In using Captopril and Hydrochlorothiazide tablets, consideration
                            should be given to the risk of neutropenia/agranulocytosis (see<linkHtml href="#S6D4C403B-F03C-434B-B6B4-FC9218D99E07">WARNINGS</linkHtml>).</paragraph>
						<paragraph>Captopril and Hydrochlorothiazide tablets may be used for
                            patients with normal renal function, in whom the risk is relatively low.
                            In patients with impaired renal function, particularly those with
                            collagen vascular disease, Captopril and Hydrochlorothiazide tablets                            should be reserved for hypertensives who have either developed
                            unacceptable side effects on other drugs, or have failed to respond
                            satisfactorily to other drug combinations.</paragraph>
						<paragraph>ACE inhibitors (for which adequate data are available) cause a
                            higher rate of angioedema in black than in non-black patients (see<linkHtml href="#S68DA1A5D-5D69-4CCF-B8B1-2DF58A95B8B0">WARNINGS:
                                Angioedema</linkHtml>).</paragraph>
					</text>
					<effectiveTime value="20060216"/>
				</section>
			</component>
			<component>
				<section ID="S30AC706B-ECBC-4A3B-9591-22CB4E9BF781">
					<id root="F8008B18-B4B6-6201-71F2-9BE8CC19E05B"/>
					<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS"/>
					<title mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
					<effectiveTime value="20060216"/>
					<component>
						<section ID="SCB62CF19-C8DB-4F1F-8CCF-B28F16D0D5E5">
							<id root="1BCB86AB-7068-029F-623B-169F234D1F7C"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
							<title mediaType="text/x-hl7-title+xml">Captopril</title>
							<text>
								<paragraph>This product is contraindicated in patients who are
                                    hypersensitive to captopril or any other angiotensin-converting
                                    enzyme inhibitor (e.g., a patient who has experienced angioedema
                                    during therapy with any other ACE inhibitor).</paragraph>
							</text>
							<effectiveTime value="20060216"/>
						</section>
					</component>
					<component>
						<section ID="SEE1F9A26-C351-4920-94C2-1C3395FF4753">
							<id root="79E8A8C8-FF5F-179C-3268-F29A796C4590"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
							<title mediaType="text/x-hl7-title+xml">Hydrochlorothiazide</title>
							<text>
								<paragraph>Hydrochlorothiazide is contraindicated in anuria. It is
                                    also contraindicated in patients who have previously                               demonstrated hypersensitivity to hydrochlorothiazide or other
                                    sulfonamide-derived drugs.</paragraph>
							</text>
							<effectiveTime value="20060216"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section ID="S6D4C403B-F03C-434B-B6B4-FC9218D99E07">
					<id root="F5138179-2219-2A0A-F5C1-ECE774C8CDB8"/>
					<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS"/>
					<title mediaType="text/x-hl7-title+xml">WARNINGS</title>
					<effectiveTime value="20060216"/>
					<component>
						<section ID="S20F53A3D-67EB-41FB-ACAA-B344FA886A46">
							<id root="60852394-EE51-AAE5-DEB3-96AAF6A08DA9"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
							<title mediaType="text/x-hl7-title+xml">Captopril</title>
							<effectiveTime value="20060216"/>
							<component>
								<section ID="S8C7DFCE0-2BF7-4BC5-B068-6F9B86C03341">
									<id root="9067176B-6457-E491-DEDD-159A8F98CDFE"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Anaphylactoid and Possibly Related Reactions</title>
									<text>
										<paragraph>Presumably because angiotensin-converting enzyme
                                            inhibitors affect the metabolism of eicosanoids and
                                            polypeptides, including endogenous bradykinin, patients
                                            receiving ACE inhibitors (including Captopril and
                                            Hydrochlorothiazide tablets) may be subject to a variety
                                            of adverse reactions, some of them serious.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S68DA1A5D-5D69-4CCF-B8B1-2DF58A95B8B0">
									<id root="28BDA1F6-5B9B-3EE7-1423-3BF9437BB124"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Angioedema</title>
									<text>
										<paragraph>Angioedema involving the extremities, face, lips,
                                            mucous membranes, tongue, glottis or larynx has been
                                            seen in patients treated with ACE inhibitors, including
                                            captopril. If angioedema involves the tongue, glottis or
                                            larynx, airway obstruction may occur and be fatal.
                                            Emergency therapy, including but not necessarily limited                        to, subcutaneous administration of a 1:1000 solution of
                                            epinephrine should be promptly instituted. </paragraph>
										<paragraph>Swelling confined to the face, mucous membranes
                                            of the mouth, lips and extremities has usually resolved
                                            with discontinuation of treatment; some cases required
                                            medical therapy. (See&#160;<linkHtml href="#S6A71DAC9-C71E-45C3-BC01-87C0B1C3A85C">PRECAUTIONS: Information for
                                            Patients</linkHtml>&#160;and <linkHtml href="#S29A07741-3494-4F89-B323-16BBE0634907">ADVERSE REACTIONS:
                                        Captopril</linkHtml>.)</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S99921428-79CF-4D5D-81FF-9549A3A6DD84">
									<id root="51A9C62E-61AA-C9C1-211F-C824BD48105D"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Anaphylactoid reactions during desensitization</title>
									<text>
										<paragraph>Two patients undergoing desensitizing treatment
                                            with hymenoptera venom while receiving ACE inhibitors
                                            sustained life-threatening anaphylactoid reactions. In           the same patients, these reactions were avoided when ACE
                                            inhibitors were temporarily withheld, but they
                                            reappeared upon inadvertent rechallenge.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S3C3C19E7-BC88-4843-BA1A-40BC42D90435">
									<id root="2A749E94-E813-8B76-5D15-7CBDCCB2B0A5"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Anaphylactoid reactions during membrane exposure</title>
									<text>
										<paragraph>Anaphylactoid reactions have been reported in
                                            patients dialyzed with high-flux membranes and treated
                                            concomitantly with an ACE inhibitor. Anaphylactoid
                                            reactions have also been reported in patients undergoing
                                            low-density lipoprotein apheresis with dextran sulfate
                                            absorption.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S099C4A80-1049-4C44-885E-E2E00DDFD8A5">
									<id root="41108A01-ABED-02D9-3B61-6D33F6C9D3B4"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Neutropenia/Agranulocytosis</title>
									<text>
										<paragraph>Neutropenia (&lt;1000/mm<sup>3</sup>) with
                                            myeloid hypoplasia has resulted from use of captopril.
                                            About half of the neutropenic patients developed
                                            systemic or oral cavity infections or other features of
                                            the syndrome of agranulocytosis.</paragraph>
										<paragraph>The risk of neutropenia is dependent on the
                                            clinical status of the patient:</paragraph>
										<paragraph>In clinical trials in patients with hypertension
                                            who have normal renal function (serum creatinine less
                                            than 1.6 mg/dL and no collagen vascular disease),
                                            neutropenia has been seen in one patient out of over
                                            8,600 exposed.</paragraph>
										<paragraph>In patients with some degree of renal failure
                                            (serum creatinine at least 1.6 mg/dL) but no collagen
                                            vascular disease, the risk of neutropenia in clinical
                                            trials was about 1 per 500, a frequency over 15 times
                                            that for uncomplicated hypertension. Daily doses of
                                            captopril were relatively high in these patients,
                                            particularly in view of their diminished renal function.
                                            In foreign marketing experience in patients with renal
                                            failure, use of allopurinol concomitantly with captopril                                        has been associated with neutropenia but this
                                            association has not appeared in U.S. reports.</paragraph>
										<paragraph>In patients with collagen vascular diseases
                                            (e.g., systemic lupus erythematosus, scleroderma) and
                                            impaired renal function, neutropenia occurred in 3.7
                                            percent of patients in clinical trials.</paragraph>
										<paragraph>While none of the over 750 patients in formal
                                            clinical trials of heart failure developed neutropenia,
                                            it has occurred during the subsequent clinical
                                            experience. About half of the reported cases had serum
                                            creatinine &#8805;1.6 mg/dL and more than 75 percent
                                            were in patients also receiving procainamide. In heart
                                            failure, it appears that the same risk factors for
                                            neutropenia are present.</paragraph>
										<paragraph>The neutropenia has usually been detected within
                                            three months after captopril was started. Bone marrow
                                            examinations in patients with neutropenia consistently
                                            showed myeloid hypoplasia, frequently accompanied by
                                            erythroid hypoplasia and decreased numbers of
                                            megakaryocytes (e.g., hypoplastic bone marrow and
                                            pancytopenia); anemia and thrombocytopenia were                                         sometimes seen.</paragraph>
										<paragraph>In general, neutrophils returned to normal in
                                            about two weeks after captopril was discontinued, and
                                            serous infections were limited to clinical complex
                                            patients. About 13 percent of the cases of neutropenia
                                            have ended fatally, but almost all fatalities were in
                                            patients with serious illness, having collagen vascular
                                            disease, renal failure, heart failure or
                                            immunosuppressant therapy, or a combination of these
                                            complicating factors.</paragraph>
										<paragraph>
											<content styleCode="bold">Evacuation of the hypertensive
                                                or heart failure patient should always include
                                                assessment of renal function.</content>
										</paragraph>
										<paragraph>If captopril is used in patients with impaired
                                            renal function, white blood cell and differential counts
                                            should be evaluated prior to starting treatment and at
                                            approximately two-week intervals for about three months,
                                            then periodically.</paragraph>
										<paragraph>In patients with collagen vascular disease or who
                                            are exposed to other drugs known to affect the white
                                            cells or immune response, particularly when there is
                                            impaired renal function, captopril should be used only
                                            after assessment of benefit and risk, and then with
                                            caution.</paragraph>
										<paragraph>All patients treated with captopril should be
                                            told to report any signs of infection (e.g., sore
                                            throat, fever). If infection is suspected, white cell
                                            counts should be performed without delay.</paragraph>
										<paragraph>Since discontinuation of captopril and other
                                            drugs has generally led to prompt return of the white
                                            count to normal, upon confirmation of neutropenia
                                            (neutrophils count &lt;1000/mm<sup>3</sup>) the
                                            physician should withdraw captopril and closely follow
                                            the patient&#8217;s course.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="SE47B8EA2-DCF7-4A0E-8837-0D70757B9D02">
									<id root="4C4057BE-2238-8787-6849-542D9C598598"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Proteinuria</title>
									<text>
										<paragraph>Total urinary proteins greater than 1 g per day
                                            were seen in about 0.7 percent of patients receiving
                                            captopril. About 90 percent of affected patients had
                                            evidence of prior renal disease or received relatively
                                            high doses of captopril (in excess of 150 mg/day), or
                                            both. The nephrotic syndrome occurred in about one-fifth
                                            of proteinuric patients. In most cases, proteinuria
                                            subsided or cleared within six months whether or not
                                            captopril was continued. Parameters of renal function,
                                            such as BUN and creatinine, were seldom altered in the
                                            patients with proteinuria.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="SE3090A53-ECC8-4588-AD1C-49B1DC93BE68">
									<id root="D559452B-0F9D-3316-BC14-2B2C3FFA6C5A"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Hypotension</title>
									<text>
										<paragraph>Excessive hypotension was rarely seen in
                                            hypertensive patients but is a possible consequence of
                                            captopril use in salt/volume depleted persons (such as
                                            those treated vigorously with diuretics), patients with
                                            heart failure or those patients undergoing renal
                                            dialysis. (See <linkHtml href="#S00239F77-7924-42B6-9B10-4C1FD80BD423">PRECAUTIONS: Drug
                                        Interactions</linkHtml>.)</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="SCC1D9261-A090-4EED-9B40-B8882FBEDA01">
									<id root="F1E084E2-690F-E31A-2D11-44BB22FB1355"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Fetal/Neonatal Morbidity and Mortality</title>
									<text>
										<paragraph>ACE inhibitors can cause fetal and neonatal
                                            morbidity and death when administered to pregnant women.
                                            Several dozen cases have been reported in the world
                                            literature. When pregnancy is detected, ACE inhibitors
                                            should be discontinued as soon as possible.</paragraph>
										<paragraph>The use of ACE inhibitors during the second and
                                            third trimesters of pregnancy has been associated with
                                            fetal and neonatal injury, including hypotension,
                                            neonatal skull hypoplasia, anuria, reversible or
                                            irreversible renal failure, and death. Oligohydramnios
                                            has also been reported, presumably resulting from
                                            decreased fetal renal function; oligohydramnios in this
                                            setting has been associated with fetal limb
                                            contractures, craniofacial deformation, and hypoplastic
                                            lung development. Prematurity, intrauterine growth
                                            retardation, and patent ductus arteriosus have also been
                                            reported, although it is not clear whether these
                                            occurrences were due to the ACE-inhibitor exposure.</paragraph>
										<paragraph>These adverse effects do not appear to have
                                            resulted from intrauterine ACE-inhibitor exposure that
                                            has been limited to the first trimester. Mothers whose
                                            embryos and fetuses are exposed to ACE inhibitors only
                                            during the first trimester should be so informed.           Nonetheless, when patients become pregnant, physicians
                                            should make every effort to discontinue the use of
                                            captopril as soon as possible.</paragraph>
										<paragraph>Rarely (probably less often than once in every
                                            thousand pregnancies), no alternative to ACE inhibitors
                                            will be found. In these rare cases, the mothers should
                                            be apprised of the potential hazards to their fetuses,
                                            and serial ultrasound examinations should be performed
                                            to assess the intraamniotic environment.</paragraph>
										<paragraph>If oligohydramnios is observed, captopril should
                                            be discontinued unless it is considered life-saving for
                                            the mother. Contraction stress testing (CST), a
                                            non-stress test (NST), or biophysical profiling (BPP)
                                            may be appropriate, depending upon the week of
                                            pregnancy. Patients and physicians should be aware,
                                            however, that oligohydramnios may not appear until after
                                            the fetus has sustained irreversible injury.</paragraph>
										<paragraph>Infants with histories of <content styleCode="italics">in utero</content> exposure to
                                            ACE inhibitors should be closely observed for
                                            hypotension, oliguria, and hyperkalemia. If oliguria
                                            occurs, attention should be directed toward support of
                                            blood pressure and renal perfusion. Exchange transfusion
                                            or dialysis may be required as a means of reversing
                                            hypotension and/or substituting for disordered renal
                                            function. While captopril may be removed from the adult
                                            circulation by hemodialysis, there is inadequate data
                                            concerning the effectiveness of hemodialysis for
                                            removing it from the circulation of neonates or
                                            children. Peritoneal dialysis is not effective for
                                            removing captopril; there is no information concerning
                                            exchange transfusion for removing captopril from the
                                            general circulation.</paragraph>
										<paragraph>When captopril was given to rabbits at doses
                                            about 0.8 to 70 times (on a mg/kg basis) the maximum
                                            recommended human dose, low incidences of craniofacial
                                            malformations were seen. N0 teratogenic effects of
                                            captopril were seen in studies of pregnant rats and
                                            hamsters. On a mg/kg basis, the doses used were up to
                                            150 times (in hamsters) and 625 times (in rats) the
                                            maximum recommended human dose.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="SDB683824-6837-4B1B-A087-62E4EC2F8D92">
									<id root="EF7F1ECC-67D5-99AA-E5C9-CCEC198E027D"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Hepatic Failure</title>
									<text>
										<paragraph>Rarely, ACE inhibitors have been associated with
                                            a syndrome that starts with cholestatic jaundice and
                                            progresses to fulminant hepatic necrosis and (sometimes)
                                            death. The mechanism of this syndrome is not understood.
                                            Patients receiving ACE inhibitors who develop jaundice
                                            or marked elevations of hepatic enzymes should
                                            discontinue the ACE inhibitor and receive appropriate
                                            medical follow-up.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section ID="S48E1893B-ACBF-4F3D-811C-410CA0E15EBC">
							<id root="97F305C6-2CFD-4979-61D2-3EFC91CE6109"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
							<title mediaType="text/x-hl7-title+xml">Hydrochlorothiazide</title>
							<text>
								<paragraph>Thiazides should be used with caution in severe renal
                                    disease. In patients with renal disease, thiazides may
                                    precipitate azotemia. Cumulative effects of the drug may develop
                                    in patients with impaired renal function. </paragraph>
								<paragraph>Thiazides should be used with caution in patients with
                                    impaired hepatic function or progressive liver disease, since
                                    minor alterations of fluid and electrolyte balance may
                                    precipitate hepatic coma. </paragraph>
								<paragraph>Sensitivity reactions may occur in patients with or
                                    without a history of allergy or bronchial asthma. </paragraph>
								<paragraph>The possibility of exacerbation or activation of systemic
                                    lupus erythematosus has been reported. </paragraph>
								<paragraph>In general, lithium should not be given with diuretics
                                    (see <linkHtml href="#S8CB6367F-E1DE-4EFC-8821-E8512B022BC6">PRECAUTIONS: Drug Interactions,
                                    Hydrochlorothiazide</linkHtml>).</paragraph>
							</text>
							<effectiveTime value="20060216"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section ID="S8CDFE52C-D917-4E32-A56C-F235126FA404">
					<id root="40B7E691-3A5C-1CFF-B647-622FE1EA89C3"/>
					<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PRECAUTIONS"/>
					<title mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
					<effectiveTime value="20060216"/>
					<component>
						<section ID="SD5F90B14-7D72-4E57-A604-656378D2224E">
							<id root="7CC2F140-4296-D284-F5DA-E3DA8C92D700"/>
							<code code="34072-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GENERAL PRECAUTIONS"/>
							<title mediaType="text/x-hl7-title+xml">General</title>
							<effectiveTime value="20060216"/>
							<component>
								<section ID="SCAC058B4-2552-40F0-B123-938718E6484C">
									<id root="02D2F666-F15C-BB61-FBED-5EE5383C625E"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Captopril</title>
									<effectiveTime value="20060216"/>
									<component>
										<section ID="S7D0A415C-475A-45FA-8C4E-C316315A25CF">
											<id root="E9B2142C-2E05-B98A-8F2B-7EAC1DC57EC8"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Impaired Renal Function</title>
											<text>
												<paragraph>Some patients with renal disease,
                                                  particularly those with severe renal artery
                                                  stenosis, have developed increases in BUN and
                                                  serum creatinine after reduction of blood
                                                  pressure with captopril. Captopril dosage
                                                  reduction and/or discontinuation of diuretic may
                                                  be required. For some of these patients, it may
                                                  not be possible to normalize blood pressure and
                                                  maintain adequate renal perfusion (see <linkHtml href="#SCCC5CBEB-854C-43E0-BCC8-DC43163F71D5">CLINICAL PHARMACOLOGY</linkHtml>, <linkHtml href="#S752E7393-5D07-4A52-90E8-958DE89434A6">DOSAGE AND ADMINISTRATION</linkHtml>,<linkHtml href="#S61981536-EE69-4696-BBCE-56508AC9E9A2">ADVERSE REACTIONS: Altered Laboratory
                                                  Findings</linkHtml>).</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="S18089810-C4FA-4CBC-AB0D-8159E9B0516B">
											<id root="E2735EED-C4E6-1436-91AF-5AF05A6A86CF"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Hyperkalemia</title>
											<text>
												<paragraph>Elevations in serum potassium have been
                                                  observed in some patients treated with ACE                                           inhibitors, including captopril. When treated
                                                  with ACE inhibitors, patients at risk for the
                                                  development of hyperkalemia include those with:
                                                  renal insufficiency; diabetes mellitus; and
                                                  those using concomitant potassium-sparing
                                                  diuretics, potassium supplements or
                                                  potassium-containing salt substitutes; or other
                                                  drugs associated with increases in serum
                                                  potassium. (See&#160;<linkHtml href="#S6A71DAC9-C71E-45C3-BC01-87C0B1C3A85C">PRECAUTIONS: Information for
                                                  Patients</linkHtml> and <linkHtml href="#S4B7DC53A-B563-47FC-909E-94CF4E248AB5">Drug Interactions, Captopril</linkHtml>;<linkHtml href="#S61981536-EE69-4696-BBCE-56508AC9E9A2">ADVERSE REACTIONS: Altered Laboratory
                                                  Findings</linkHtml>.)</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="S5C30395E-04BA-4CA9-9CD7-5B1E1EB3EEAA">
											<id root="A6D201A3-63CF-9CE3-011D-3FF383B65C1F"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Cough</title>
											<text>
												<paragraph>Presumably due to the inhibition of the
                                                  degradation of endogenous bradykinin, persistent
                                                  nonproductive cough has been reported with all                          ACE inhibitors, always resolving after
                                                  discontinuation of therapy. ACE
                                                  inhibitor-induced cough should be considered in
                                                  the differential diagnosis of cough.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="S30471A56-25FD-4CB4-BADD-ECCE8E977C4D">
											<id root="A7446E2C-518D-BC1F-7C47-99A419518CE1"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Surgery/Anesthesia</title>
											<text>
												<paragraph>In patients undergoing major surgery or
                                                  during anesthesia with agents that produce
                                                  hypotension, captopril will block angiotensin II
                                                  formation secondary to compensatory renin
                                                  release. If hypotension occurs and is considered
                                                  to be due to this mechanism, it can be corrected
                                                  by volume exposure.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="S896196D0-C248-48EF-9135-7938B0805E28">
											<id root="B2EB63CA-8504-5704-7031-AACEDD80960E"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Hemodialysis</title>
											<text>
												<paragraph>Recent clinical observations have shown                                         an association of hypersensitivity-like
                                                  (anaphylactoid) reactions during hemodialysis
                                                  with high-flux dialysis membranes (e.g., AN69)
                                                  in patients receiving ACE inhibitors as
                                                  medication. In these patients, consideration
                                                  should be given to using a different type of
                                                  dialysis membrane or a different class of
                                                  medication. (See <linkHtml href="#S3C3C19E7-BC88-4843-BA1A-40BC42D90435">WARNINGS: Captopril: Anaphylactoid
                                                  reactions during membrane
                                                  exposure</linkHtml>.)</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
								</section>
							</component>
							<component>
								<section ID="S4494C826-7321-4A35-B732-8853013419FC">
									<id root="B93933BA-87F0-2DA6-487D-8F4B56121EA7"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Hydrochlorothiazide</title>
									<text>
										<paragraph>Periodic determination of serum electrolytes to
                                            detect possible electrolyte imbalance should be performed at appropriate intervals.</paragraph>
										<paragraph>All patients receiving thiazide therapy should be
                                            observed for clinical signs of fluid or electrolyte
                                            imbalance, namely: hyponatremia, hypochloremic
                                            alkalosis, and hypokalemia. Serum and urine electrolyte
                                            determinations are particularly important when the
                                            patient is vomiting excessively or receiving parenteral
                                            fluids. Warning signs or symptoms of fluid and
                                            electrolyte imbalance may include: dryness of mouth,
                                            thirst, weakness, lethargy, drowsiness, restlessness,
                                            muscle pains or cramps, muscular fatigue, hypotension,
                                            oliguria, tachycardia, and gastrointestinal disturbances
                                            such as nausea and vomiting.</paragraph>
										<paragraph>Hypokalemia may develop, especially with brisk
                                            diuresis, or when severe cirrhosis is present.
                                            Interference with adequate oral electrolyte intake will
                                            also contribute to hypokalemia. Hypokalemia can
                                            sensitize or exaggerate the response of the heart to the
                                            toxic effects of digitalis (e.g., increased ventricular
                                            irritability). Because captopril reduces the production
                                            of aldosterone, concomitant therapy with captopril
                                            reduces the diuretic-induced hypokalemia. Fewer patients
                                            may require potassium supplements and/or foods with a
                                            high potassium content (see <linkHtml href="#S433ACD18-EC11-475D-A328-51113E443742">Drug
                                                Interactions, Agents Increasing Serum
                                            Potassium</linkHtml>).</paragraph>
										<paragraph>Any chloride deficit is generally mild and
                                            usually does not require specific treatment except under
                                            extraordinary circumstances (as in liver disease or
                                            renal disease). Dilutional hyponatremia may occur in
                                            edematous patients in hot weather; appropriate therapy
                                            is water restriction, rather than administration of salt
                                            except in rare instances when the hyponatremia is
                                            life-threatening. In actual salt depletion, appropriate
                                            replacement is the therapy of choice. </paragraph>
										<paragraph>Hyperuricemia may occur or frank gout may be
                                            precipitated in certain patients receiving thiazide
                                            therapy.</paragraph>
										<paragraph>Latent diabetes mellitus may become manifest
                                            during thiazide administration. </paragraph>
										<paragraph>The antihypertensive effect of thiazide diuretics
                                            may be enhanced in the postsympathectomy patient.</paragraph>
										<paragraph>If progressive renal impairment becomes evident,
                                            as indicated by a rising nonprotein nitrogen or blood
                                            urea nitrogen (BUN), a careful reappraisal of therapy is
                                            necessary with consideration given to withholding or
                                            discontinuing diuretic therapy. </paragraph>
										<paragraph>Thiazides may decrease serum PBI levels without
                                            signs of thyroid disturbance. </paragraph>
										<paragraph>Calcium excretion is decreased by thiazides.
                                            Pathological changes in the parathyroid gland with
                                            hypercalcemia and hypophosphatemia have been observed in
                                            a few patients on prolonged thiazide therapy. The common
                                            complications of hyperparathyroidism such as renal
                                            lithiasis, bone resorption, and peptic ulceration have
                                            not been seen. Thiazides should be discontinued before
                                            carrying out tests for parathyroid function. </paragraph>
										<paragraph>Thiazides have been shown to increase the urinary
                                            excretion of magnesium; this may result in
                                            hypomagnesemia.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section ID="S6A71DAC9-C71E-45C3-BC01-87C0B1C3A85C">
							<id root="D052813C-25EC-2D5C-55DD-CFCFF5843523"/>
							<code code="34076-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INFORMATION FOR PATIENTS"/>
							<title mediaType="text/x-hl7-title+xml">Information for Patients</title>
							<text>
								<paragraph>Patients should be advised to immediately report to their
                                    physician any signs or symptoms suggesting angioedema (e.g.,
                                    swelling of face, eyes, lips, tongue, larynx and extremities;
                                    difficulty in swallowing or breathing; hoarseness) and to
                                    discontinue therapy. (See <linkHtml href="#S68DA1A5D-5D69-4CCF-B8B1-2DF58A95B8B0">WARNINGS:
                                        Captopril: Angioedema</linkHtml>.)</paragraph>
								<paragraph>Patients should be told to report promptly any indication
                                    of infection (e.g., sore throat, fever), which may be a sign of
                                    neutropenia, or of progressive edema which might be related to
                                    proteinuria and nephrotic syndrome.</paragraph>
								<paragraph>All patients should be cautioned that excessive
                                    perspiration and dehydration may lead to an excessive fall in
                                    blood pressure because of reduction in fluid volume. Other
                                    causes of volume depletion such as vomiting or diarrhea may also
                                    lead to a fall in blood pressure; patients should be advised to
                                    consult with the physician.</paragraph>
								<paragraph>Patients should be advised not to use potassium-sparing
                                    diuretics, potassium supplements or potassium-containing salt
                                    substitutes without consulting their physicians.
                                        (See&#160;<linkHtml href="#SD5F90B14-7D72-4E57-A604-656378D2224E">PRECAUTIONS:
                                        General</linkHtml> and <linkHtml href="#S4B7DC53A-B563-47FC-909E-94CF4E248AB5">Drug
                                        Interactions, Captopril</linkHtml>; <linkHtml href="#S29A07741-3494-4F89-B323-16BBE0634907">ADVERSE
                                        REACTIONS: Captopril</linkHtml>.)</paragraph>
								<paragraph>Patients should be warned against interruption or
                                    discontinuation of medication unless instructed by the
                                    physician. </paragraph>
								<paragraph>Heart failure patients on captopril therapy should be
                                    cautioned against rapid increases in physical activity.</paragraph>
								<paragraph>Patients should be informed that Captopril and
                                    Hydrochlorothiazide tablets should be taken one hour before
                                    meals (see <linkHtml href="#S752E7393-5D07-4A52-90E8-958DE89434A6">DOSAGE AND
                                        ADMINISTRATION</linkHtml>).</paragraph>
							</text>
							<effectiveTime value="20060216"/>
						</section>
					</component>
					<component>
						<section ID="S477BB88A-BD5F-454B-BA4A-C87112EBC167">
							<id root="AB4ACF2B-B1CB-B95C-8E43-71CBE4A98880"/>
							<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PREGNANCY"/>
							<title mediaType="text/x-hl7-title+xml">Pregnancy</title>
							<text>
								<paragraph>Female patients of childbearing age should be told about
                                    the consequences of second- and third-trimester exposure to ACE
                                    inhibitors, and they should also be told that these consequences
                                    do not appear to have resulted from intrauterine ACE-inhibitor
                                    exposure that has been limited to the first trimester. These
                                    patients should be asked to report pregnancies to their
                                    physicians as soon as possible.</paragraph>
							</text>
							<effectiveTime value="20060216"/>
						</section>
					</component>
					<component>
						<section ID="SDF64FCB5-FC5E-49CB-82D7-5DFDDB81CA73">
							<id root="78E9FE2A-F580-A213-EBDD-7EE905BB9CD2"/>
							<code code="34075-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="LABORATORY TESTS"/>
							<title mediaType="text/x-hl7-title+xml">Laboratory Tests</title>
							<text>
								<paragraph>Serum electrolyte levels should be regularly monitored
                                        (see&#160;<linkHtml href="#S20F53A3D-67EB-41FB-ACAA-B344FA886A46">WARNINGS:                         Captopril</linkHtml> and <linkHtml href="#S48E1893B-ACBF-4F3D-811C-410CA0E15EBC">Hydrochlorothiazide</linkHtml>; <linkHtml href="#S4494C826-7321-4A35-B732-8853013419FC">PRECAUTIONS:
                                        General, Hydrochlorothiazide</linkHtml>).</paragraph>
							</text>
							<effectiveTime value="20060216"/>
						</section>
					</component>
					<component>
						<section ID="S00239F77-7924-42B6-9B10-4C1FD80BD423">
							<id root="A33CBF17-7546-23FF-AC8A-7343F3A295FF"/>
							<code code="34073-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DRUG INTERACTIONS"/>
							<title mediaType="text/x-hl7-title+xml">Drug Interactions</title>
							<effectiveTime value="20060216"/>
							<component>
								<section ID="S4B7DC53A-B563-47FC-909E-94CF4E248AB5">
									<id root="1CB645C0-FFED-B9CD-214F-92496F8BE009"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Captopril</title>
									<effectiveTime value="20060216"/>
									<component>
										<section ID="S25ED4773-E310-4260-9E7F-D8741EB68127">
											<id root="42A0A9EE-170F-78E4-5EF9-BDB9B989446A"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Hypotension &#8211; Patients on Diuretic
                                                Therapy</title>
											<text>
												<paragraph>Patients on diuretics and especially
                                                  those in whom diuretic therapy was recently
                                                  instituted, as well as those on severe dietary
                                                  salt restriction or dialysis, may occasionally     experience a precipitous reduction of blood                                        pressure usually within the first hour after
                                                  receiving the initial dose of captopril.</paragraph>
												<paragraph>The possibility of hypotensive effects
                                                  with captopril can be minimized by either
                                                  discontinuing the diuretic or increasing the
                                                  salt intake approximately one week prior to
                                                  initiation of treatment with captopril or
                                                  initiating therapy with small doses (6.25 or
                                                  12.5 mg). Alternatively, provide medical
                                                  supervision for at least one hour after the
                                                  initial dose. If hypotension occurs, the patient
                                                  should be placed in a supine position and, if
                                                  necessary, receive an intravenous infusion of
                                                  normal saline. This transient hypotensive
                                                  response is not a contraindication to further
                                                  doses which can be given without difficulty once
                                                  the blood pressure has increased after volume
                                                  expansion.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="S2F5E5476-01C6-440D-AE11-EA004FEBABFA">
											<id root="9B7539D3-D77E-AE35-3A85-764A1ADD48E5"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Agents Having Vasodilator Activity</title>
											<text>
												<paragraph>Data on the effect of concomitant use of
                                                  other vasodilators in patients receiving
                                                  captopril for heart failure are not available;
                                                  therefore, nitroglycerin or other nitrates (as
                                                  used for management of angina) or other drugs
                                                  having vasodilator activity should, if possible,
                                                  be discontinued before starting captopril. If
                                                  resumed during captopril therapy, such agents
                                                  should be administered cautiously, and perhaps
                                                  at lower dosage.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="SD1587694-BE1F-46A5-8509-01ABFAD378A7">
											<id root="DFF7FE60-A7AE-E485-20E4-0605CC316751"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Agents Causing Renin Release</title>
											<text>
												<paragraph>Captopril&#8217;s effect will be
                                                  augmented by antihypertensive agents that cause
                                                  renin release. For example, diuretics (e.g.,
                                                  thiazides) may activate the
                                                  renin-angiotensin-aldosterone        system.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="S83843F15-0FD8-44E2-B71C-3C11183A589D">
											<id root="3A1E7908-25BE-7A73-878C-F1001A51E64F"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Agents Affecting Sympathetic Activity</title>
											<text>
												<paragraph>The sympathetic nervous system may be
                                                  especially important in supporting blood
                                                  pressure in patients receiving captopril alone
                                                  or with diuretics. Therefore, agents affecting
                                                  sympathetic activity (e.g., ganglionic blocking
                                                  agents or adrenergic neuron blocking agents)                                  should be used with caution. Beta-adrenergic
                                                  blocking drugs add some further antihypertensive
                                                  effect to captopril, but the overall response is
                                                  less than additive.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="S433ACD18-EC11-475D-A328-51113E443742">
											<id root="983C6244-BB01-2152-E5E9-A3A66B377F07"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Agents Increasing Serum Potassium</title>
											<text>
												<paragraph>Since captopril decreases aldosterone
                                                  production, elevation of serum potassium may
                                                  occur. Potassium-sparing diuretics such as
                                                  spironolactone, triamterene, or amiloride, or
                                                  potassium supplements, should be given only for
                                                  documented hypokalemia, and then with caution,
                                                  since they may lead to a significant increase of
                                                  serum potassium. Salt substitutes containing
                                                  potassium should also be used with
                                                caution.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="SD9E63EA8-7834-4967-8E33-40291AB968B3">
											<id root="298EB71A-2598-166E-A7DD-8EAAB073AD5A"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Inhibitors Of Endogenous Prostaglandin Synthesis</title>
											<text>
												<paragraph>It has been reported that indomethacin
                                                  may reduce the antihypertensive effect of
                                                  captopril, especially in cases of low renin
                                                  hypertension. Other nonsteroidal
                                                  anti-inflammatory agents (e.g., aspirin) may
                                                  also have this effect.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="S0A5A15EA-3074-4C72-B4BE-25D55634A5E0">
											<id root="24445654-6C0E-0F7C-1F4B-E08CD3608DD8"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Lithium</title>
											<text>
												<paragraph>Increased serum lithium levels and
                                                  symptoms of lithium toxicity have been reported
                                                  in patients receiving concomitant lithium and
                                                  ACE inhibitor therapy. These drugs should be
                                                  coadministered with caution and frequent
                                                  monitoring of serum lithium levels is
                                                  recommended. If a diuretic is also used, it may
                                                  increase the risk of lithium toxicity (see<linkHtml href="#SC8521EA8-5ED2-49EE-84FF-566451956645">PRECAUTIONS: Drug Interactions,
                                                  Hydrochlorothiazide,
                                                Lithium</linkHtml>).</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
								</section>
							</component>
							<component>
								<section ID="S8CB6367F-E1DE-4EFC-8821-E8512B022BC6">
									<id root="B51D3115-DC12-6531-6B65-D6178E215ED9"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Hydrochlorothiazide</title>
									<text>
										<paragraph>When administered concurrently the following
                                            drugs may interact with thiazide diuretics:</paragraph>
									</text>
									<effectiveTime value="20060216"/>
									<component>
										<section ID="S4741B21A-8D08-4CE0-B099-300E79251E4F">
											<id root="89520FB6-5557-324A-F84E-C7C3629C1B48"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Alcohol, barbiturates, or narcotics &#8211;</title>
											<text>
												<paragraph>potentiation of orthostatic hypotension
                                                  may occur.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="S3CDB7813-FF9E-4E2C-9C54-A1D93A815B02">
											<id root="A1193BEF-5738-BD16-6C3E-B9D77FF95720"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Amphotericin B, corticosteroids, or
                                                corticotrophin (ACTH) &#8211;</title>
											<text>
												<paragraph>may intensify electrolyte imbalance,
                                                  particularly hypokalemia. Monitor potassium                          levels; use potassium replacements if
                                                necessary.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="S3997B63C-D76C-4FFD-9226-75F495EA5739">
											<id root="2D0AED8F-29E1-9640-DB10-391AAD2AF8DC"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Anticoagulants (oral) &#8211;</title>
											<text>
												<paragraph>dosage adjustments of anticoagulant
                                                  medication may be necessary since
                                                  hydrochlorothiazide may decrease their
                                                effects.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="S442F03BB-3235-41C0-B458-67889F9FD5E9">
											<id root="69C1915D-6189-DEA0-8D24-4A8D858062E2"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Antigout medications &#8211;</title>
											<text>
												<paragraph>dosage adjustments of antigout medication
                                                  may be necessary since hydrochlorothiazide may
                                                  raise the level of blood uric acid.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="S628C0127-1834-4640-8E2D-35B86BF9C1F1">
											<id root="A129C0E8-AD91-9F7C-31D7-9C215DC09BA7"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Other antihypertensive medications (e.g.,
                                                ganglionic or peripheral adrenergic blocking agents)&#8211;</title>
											<text>
												<paragraph>dosage adjustments may be necessary since
                                                  hydrochlorothiazide may potentiate their
                                                  effects.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="S47AF602F-99AD-4B81-B381-E003AA77C53E">
											<id root="ABDCCBAC-15D7-F4EA-6D9F-5511EB07CA99"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Antidiabetic drugs (oral agents and insulin)&#8211;</title>
											<text>
												<paragraph>since thiazides may elevate blood glucose
                                                  levels, dosage adjustments of antidiabetic
                                                  agents may be necessary.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="S78D7CB64-4C9D-40AA-B1AE-098367006D02">
											<id root="D53C4A9A-B7B0-A553-8BDD-610ED4F5EA93"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Calcium salts &#8211;</title>
											<text>
												<paragraph>increased serum calcium levels due to
                                                  decreased excretion may occur. If calcium must
                                                  be prescribed monitor serum calcium levels and
                                                  adjust calcium dosage accordingly.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="SA279C044-A2B4-437A-B99B-BC4A3F85281E">
											<id root="15CEE17A-DC1A-B67A-2FBE-65CBB2EDE08D"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Cardiac glycosides &#8211;</title>
											<text>
												<paragraph>enhanced possibility of digitalis
                                                  toxicity associated with hypokalemia. Monitor
                                                  potassium levels (see <linkHtml href="#S4B7DC53A-B563-47FC-909E-94CF4E248AB5">PRECAUTIONS: Drug Interactions,
                                                  Captopril</linkHtml>).</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="S89400EC7-BC7D-4189-96EB-2190D5334F51">
											<id root="567B1E28-F0BC-2D10-2603-2C517DB038A1"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Cholestyramine and colestipol resins &#8211;</title>
											<text>
												<paragraph>absorption of hydrochlorothiazide is
                                                  impaired in the presence of anionic exchange
                                                  resins. Single doses of either cholestyramine or
                                                  colestipol resins bind the hydrochlorothiazide
                                                  and reduce its absorption from the
                                                  gastrointestinal tract by up to 85 and 43
                                                  percent, respectively.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="SF57994E3-4969-4E2D-96F0-BE5E4C43D2AA">
											<id root="943689C0-B51B-1795-0EE3-B0551F54867F"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Diazoxide &#8211;</title>
											<text>
												<paragraph>enhanced hyperglycemic, hyperuricemic,
                                                  and antihypertensive effects. Be cognizant of
                                                  possible interaction; monitor blood glucose and
                                                  serum uric acid levels.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="SC8521EA8-5ED2-49EE-84FF-566451956645">
											<id root="25F29A98-EFBD-66A5-8634-6C1D4BA93814"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Lithium &#8211;</title>
											<text>
												<paragraph>diuretic agents reduce the renal
                                                  clearance of lithium and increase the risk of
                                                  lithium toxicity. These drugs should be
                                                  coadministered with caution and frequent
                                                  monitoring of serum lithium levels is
                                                  recommended (see <linkHtml href="#S0A5A15EA-3074-4C72-B4BE-25D55634A5E0">PRECAUTIONS: Drug Interactions, Captopril,
                                                  Lithium</linkHtml>).</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="S410C4B3B-902B-4B63-B495-25208FA12379">
											<id root="BD332A38-718C-3925-AE85-8DA87A40285F"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">MAO inhibitors &#8211;</title>
											<text>
												<paragraph>dosage adjustments of one or both agents
                                                  may be necessary since hypotensive effects are                              enhanced.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="SE9E358CB-E2DD-4E3A-8612-B43E6C496AFD">
											<id root="D344F007-73F3-C959-3315-A955CAFEB2B0"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Nondepolarizing muscle relaxants, preanesthetics
                                                and anesthetics used in surgery (e.g., tubocurarine
                                                chloride and gallamine triethiodide) &#8211;</title>
											<text>
												<paragraph>effects of these agents may be
                                                  potentiated; dosage adjustments may be required.
                                                  Monitor and correct any fluid and electrolyte
                                                  imbalances prior to surgery if
                                                feasible.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="S6CAAE07B-B588-4494-94C7-5E5B8277AD52">
											<id root="7C05145D-DB5C-87DC-5319-B96878646E0E"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Nonsteroidal anti-inflammatory agents &#8211;</title>
											<text>
												<paragraph>in some patients, the administration of a
                                                  nonsteroidal anti-inflammatory agent can reduce
                                                  the diuretic, natriuretic, and antihypertensive
                                                  effect of loop, potassium-sparing or thiazide
                                                  diuretics. Therefore, when hydrochlorothiazide
                                                  and nonsteroidal anti-inflammatory agents are
                                                  used concomitantly, the patient should be
                                                  observed closely to determine if the desired
                                                  effect of the diuretic is obtained.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="S5EC390F9-58A8-492D-AF9F-EDE11EF4DB1C">
											<id root="D773D822-FC0E-762E-BDC2-8A6EA7BE4214"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Methenamine &#8211;</title>
											<text>
												<paragraph>possible decreased effectiveness due to
                                                  alkalinization of the urine.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="SE640DEE5-8979-4140-8D56-6197A0C1A1AB">
											<id root="2C4497FD-5C32-1848-03FF-6D8DB8C5F0E9"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Pressor amines (e.g., norepinephrine) &#8211;</title>
											<text>
												<paragraph>decreased arterial responsiveness, but
                                                  not sufficient to preclude effectiveness of the
                                                  pressor agent for therapeutic use. Use caution
                                                  in patients taking both medications who undergo
                                                  surgery. Administer preanesthetic and anesthetic
                                                  agents in reduced dosage, and if possible,
                                                  discontinue hydrochlorothiazide therapy one week
                                                  prior to surgery.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
									<component>
										<section ID="SAA3E6EC7-ADF2-4471-830C-CDE21A37368C">
											<id root="1F27D84B-097F-4DD4-7BCA-29D30E741DA5"/>
											<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL                                                 UNCLASSIFIED"/>
											<title mediaType="text/x-hl7-title+xml">Probenecid or sulfinpyrazone &#8211;</title>
											<text>
												<paragraph>increased dosage of these agents may be
                                                  necessary since hydrochlorothiazide may have
                                                  hyperuricemic effects.</paragraph>
											</text>
											<effectiveTime value="20060216"/>
										</section>
									</component>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section ID="S9A684D87-883E-4F9D-A444-DD1C85A61B6C">
							<id root="0F73267C-1BB6-BC92-0B4D-117117C9592A"/>
							<code code="34074-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DRUG &amp;OR LABORATORY TEST                                 INTERACTIONS"/>
							<title mediaType="text/x-hl7-title+xml">Drug/Laboratory Test Interactions</title>
							<effectiveTime value="20060216"/>
							<component>
								<section ID="SBC82BEDC-9950-4809-88BC-73F5AC006BDF">
									<id root="17B6415F-ED7E-9A7A-0C41-107D5EA0C458"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Captopril</title>
									<text>
										<paragraph>Captopril may cause a false-positive urine test
                                            for acetone.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="SC4136D9C-C6A5-42B5-8F5A-7D8980A679CC">
									<id root="C9FBC735-3F1B-AD20-585D-1257BFDAAE68"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Hydrochlorothiazide</title>
									<text>
										<paragraph>Hydrochlorothiazide may cause diagnostic
                                            interference of the bentiromide test.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section ID="S7F25E450-0AAC-4F41-8FB4-B5B1DE8CF27D">
							<id root="F6CA80CA-B9F4-BEA4-8557-33502E34C9ED"/>
							<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CARCINOGENESIS &amp;                                 MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY"/>
							<title mediaType="text/x-hl7-title+xml">Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
							<effectiveTime value="20060216"/>
							<component>
								<section ID="SFE946390-D79C-4AC4-941E-115FA0EDEEC0">
									<id root="278D5D68-6247-EC1A-E621-618103C7D345"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Captopril</title>
									<text>
										<paragraph>Two-year studies with doses of 50 to 1350
                                            mg/kg/day in mice and rats failed to show any evidence
                                            of carcinogenic potential.</paragraph>
										<paragraph>Studies in rats have revealed no impairment of
                                            fertility.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S58251108-7F5C-4EA2-9521-BE9CEA6079A7">
									<id root="7CCF383B-7650-E77F-3D71-FC42AF82A92A"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Hydrochlorothiazide</title>
									<text>
										<paragraph>Two-year feeding studies in mice and rats
                                            conducted under the auspices of the National Toxicology
                                            Program (NTP) uncovered no evidence of a carcinogenic
                                            potential of hydrochlorothiazide in female mice (at
                                            doses of up to approximately 600 mg/kg/day) or in male
                                            and female rats (at doses of up to approximately 100
                                            mg/kg/day). The NTP, however, found equivocal evidence
                                            for hepatocarcinogenicity in male mice.</paragraph>
										<paragraph>Hydrochlorothiazide was not genotoxic in <content styleCode="italics">in vitro</content> assays using
                                            strains TA 98, TA 100, TA 1535, TA 1537 and TA 1538 of<content styleCode="italics">Salmonella
                                            typhimurium</content> (Ames assay) and in the Chinese
                                            Hamster Ovary (CHO) test for chromosomal aberrations, or<content styleCode="italics">in vivo assays using
                                                mouse germinal cell chromosomes, Chinese hamster
                                                bone marrow chromosomes, and the
                                            Drosophila</content> sex linked recessive lethal trait
                                            gene. Positive test results were obtained only in the<content styleCode="italics">in vitro</content> CHO
                                            Sister Chromatid Exchange (clastogenicity) and in the
                                            Mouse Lymphoma Cell (mutagenicity) assays, using
                                            concentrations of hydrochlorothiazide from 43 to 13&#956;g/mL, and in the <content styleCode="italics">Aspergillus nidulans</content> non-disjunction
                                            assay at an unspecified concentration.</paragraph>
										<paragraph>Hydrochlorothiazide had no adverse effects on the
                                            fertility of mice and rats of either sex in studies
                                            wherein these species were exposed, via their diet, to
                                            doses of up to 100 and 4 mg/kg, respectively, prior to
                                            conception and throughout gestation.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section ID="S7CDB204B-D3B9-4B33-BA29-34E31094004B">
							<id root="1924B5D8-5E21-C792-8E5F-C41F132F6A19"/>
							<code code="34091-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ANIMAL PHARMACOLOGY                                 &amp;OR TOXICOLOGY"/>
							<title mediaType="text/x-hl7-title+xml">Animal Toxicology</title>
							<text>
								<paragraph>Captopril <br/>Chronic oral toxicity studies were
                                    conducted in rats (2 years), dogs (47 weeks; 1 year), mice (2
                                    years), and monkeys (1 year). Significant drug-related toxicity
                                    included effects on hematopoiesis, renal toxicity,
                                    erosion/ulceration of the stomach, and variation of retinal
                                    blood vessels.</paragraph>
								<paragraph>Reductions in hemoglobin and/or hematocrit values were
                                    seen in mice, rats, and monkeys at doses 50 to 150 times the
                                    maximum recommended human dose (MRHD). Anemia, leukopenia,
                                    thrombocytopenia, and bone marrow suppression occurred in dogs
                                    at doses 8 to 30 times MRHD. The reductions in hemoglobin and
                                    hematocrit values in rats and mice were only significant at 1
                                    year and returned to normal with continued dosing by the end of
                                    the study. Marked anemia was seen at all dose levels (8 to 30                        times MRHD) in dogs, whereas moderate to marked leukopenia was
                                    noted only at 15 and 30 times MRHD and thrombocytopenia at 30
                                    times MRHD. The anemia could be reversed upon discontinuation of
                                    dosing. Bone marrow suppression occurred to a varying degree,
                                    being associated only with dogs that died or were sacrificed in
                                    a moribund condition in the 1 year study. However, in the
                                    47-week study at a dose 30 times MRHD, bone marrow suppression
                                    was found to be reversible upon continued drug administration.</paragraph>
								<paragraph>Captopril caused hyperplasia of the juxtaglomerular
                                    apparatus of the kidneys at doses 7 to 200 times the MRDH in
                                    rats and mice, at 20 to 60 times MRHD in monkeys, and at 30
                                    times the MRHD in dogs. </paragraph>
								<paragraph>Gastric erosions/ulcerations were increased in incidence
                                    at 20 and 200 times MRHD in male rats and at 30 and 65 times
                                    MRHD in dogs and monkeys, respectively. Rabbits developed
                                    gastric and intestinal ulcers when given oral doses
                                    approximately 30 times MRHD for only five to seven days. </paragraph>
								<paragraph>In the two-year rat study, irreversible and progressive
                                    variations in the caliber of retinal vessels (focal sacculations
                                    and constrictions) occurred at all dose levels (7 to 200 times
                                    MRHD) in a dose-related fashion. The effect was first observed                    in the 88<sup>th</sup> week of dosing, with a progressively
                                    increased incidence thereafter, even after cessation of
                                dosing.</paragraph>
							</text>
							<effectiveTime value="20060216"/>
						</section>
					</component>
					<component>
						<section ID="SA3921D20-4E24-4C77-9EE1-F01CCFC31FBA">
							<id root="6C09DA6A-FDC9-7312-C444-4E43E8F408CB"/>
							<code code="34077-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="TERATOGENIC EFFECTS"/>
							<title mediaType="text/x-hl7-title+xml">Pregnancy Categories C (first trimester) and D (second and third
                                trimesters)</title>
							<text>
								<paragraph>
									<content styleCode="bold">See <linkHtml href="#S29A07741-3494-4F89-B323-16BBE0634907">WARNINGS:
                                            Captopril</linkHtml>, <linkHtml href="#SCC1D9261-A090-4EED-9B40-B8882FBEDA01">Fetal/Neonatal Morbidity and
                                    Mortality</linkHtml>.</content>
								</paragraph>
							</text>
							<effectiveTime value="20060216"/>
							<component>
								<section ID="S4405A1E4-E2C0-4B6C-92BC-41FBEF30DA8D">
									<id root="3F5029AD-637D-E6F1-B9E6-4A003E6CFA4F"/>
									<code code="34078-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="NONTERATOGENIC EFFECTS"/>
									<title mediaType="text/x-hl7-title+xml">Pregnancy &#8211; Nonteratogenic Effects</title>
									<text>
										<paragraph>Hydrochlorothiazide<br/>Thiazides cross the
                                            placental barrier and appear in cord blood. The use of
                                            thiazides in pregnant women requires that the
                                            anticipated benefit be weighed against possible hazards
                                            to the fetus. These hazards include fetal or neonatal
                                            jaundice, thrombocytopenia, and possibly other adverse
                                            reactions which have occurred in the adult.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section ID="S4A73B2B0-A62B-45F3-96B8-A5B39CCAC5EF">
							<id root="C72B3EC7-7B03-9379-8B54-180EB68D2B57"/>
							<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="NURSING MOTHERS"/>
							<title mediaType="text/x-hl7-title+xml">Nursing Mothers</title>
							<text>
								<paragraph>Both captopril and hydrochlorothiazide are excreted in
                                    human milk. Because of the potential for serious adverse
                                    reactions in nursing infants from both drugs, a decision should
                                    be made whether to discontinue nursing or to discontinue therapy
                                    taking into account the importance of Captopril and
                                    Hydrochlorothiazide to the mother. (See <linkHtml href="#SAE6703C2-202D-453A-A9B8-00928657904D">PRECAUTIONS:
                                        Pediatric Use</linkHtml>.)</paragraph>
							</text>
							<effectiveTime value="20060216"/>
						</section>
					</component>
					<component>
						<section ID="SAE6703C2-202D-453A-A9B8-00928657904D">
							<id root="550C6104-076E-B1AC-C6A2-D4708B397E55"/>
							<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PEDIATRIC USE"/>
							<title mediaType="text/x-hl7-title+xml">Pediatric Use</title>
							<text>
								<paragraph>Safety and effectiveness in pediatric patients have not
                                    been established. There is limited experience reported in the
                                    literature with the use of captopril in the pediatric
                                    population; dosage, on a weight basis, was generally reported to
                                    be comparable to or less than that used in adults. </paragraph>
								<paragraph>Infants, especially newborns, may be more susceptible to
                                    the adverse hemodynamic effects of captopril. Excessive,
                                    prolonged and unpredictable decreases in blood pressure and
                                    associated complications, including oliguria and seizures, have
                                    been reported. </paragraph>
								<paragraph>Captopril and Hydrochlorothiazide should be used in
                                    pediatric patients only if other measures for controlling blood
                                    pressure have not been effective.</paragraph>
							</text>
							<effectiveTime value="20060216"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section ID="SEBCF9AC6-4CF1-439B-8C4F-9EAA56E1E3BC">
					<id root="A4A30BA2-5F50-DCB9-8CD7-727AC70DE891"/>
					<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS"/>
					<title mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
					<effectiveTime value="20060216"/>
					<component>
						<section ID="S29A07741-3494-4F89-B323-16BBE0634907">
							<id root="ED2FBA44-F93A-3D7C-CE17-518F04BBCF72"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
							<title mediaType="text/x-hl7-title+xml">Captopril</title>
							<text>
								<paragraph>Reported incidences are based on clinical trials
                                    involving approximately 7000 patients.</paragraph>
							</text>
							<effectiveTime value="20060216"/>
							<component>
								<section ID="S8262A5D5-097B-4AE4-B41B-1BEFA9280BB4">
									<id root="8A996BD6-5439-684B-7071-A1612638482B"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Renal</title>
									<text>
										<paragraph>About one of 100 patients developed proteinuria
                                            (see <linkHtml href="#S6D4C403B-F03C-434B-B6B4-FC9218D99E07">WARNINGS</linkHtml>).</paragraph>
										<paragraph>Each of the following has been reported in
                                            approximately 1 to 2 of 1000 patients and are of
                                            uncertain relationship to drug use: renal insufficiency,                                          renal failure, nephrotic syndrome, polyuria, oliguria,
                                            and urinary frequency.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S9B83F306-0AD6-4481-9DB9-3E3E3FFAB9A5">
									<id root="18FDAA61-54FC-F331-EADE-25A3B47FA521"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Hematologic</title>
									<text>
										<paragraph>Neutropenia/agranulocytosis has occurred (see<linkHtml href="#S6D4C403B-F03C-434B-B6B4-FC9218D99E07">WARNINGS</linkHtml>). Cases of anemia,
                                            thrombocytopenia, and pancytopenia have been
                                        reported.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S31B9385A-B7CB-4E6E-A972-30877D9C451B">
									<id root="F80D5114-3A28-6297-02BE-7B060B0019AB"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Dermatologic</title>
									<text>
										<paragraph>Rash, often with pruritus, and sometimes with                        fever, arthralgia, and eosinophilia, occurred in about 4
                                            to 7 (depending on renal status and dose) of 100
                                            patients, usually during the first four weeks of
                                            therapy. It is usually maculopapular, and rarely
                                            urticarial. The rash is usually mild and disappears
                                            within a few days of dosage reduction, short-term                        treatment with an antihistaminic agent, and/or
                                            discontinuing therapy; remission may occur even if
                                            captopril is continued. Pruritus, without rash, occurs
                                            in about 2 of 100 patients. Between 7 and 10 percent of
                                            patients with skin rash have shown eosinophilia and/or
                                            positive ANA titers. A reversible associated
                                            pemphigoid-like lesion, and photosensitivity, have also
                                            been reported. </paragraph>
										<paragraph>Flushing or pallor has been reported in 2 to 5 of
                                            1000 patients.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S237821BB-E2EC-4268-AA32-F4B68DCBED01">
									<id root="6E01EDEF-F4ED-8A23-1867-0599BFCB1192"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Cardiovascular</title>
									<text>
										<paragraph>Hypotension may occur; see <linkHtml href="#S6D4C403B-F03C-434B-B6B4-FC9218D99E07">WARNINGS </linkHtml>and&#160;<linkHtml href="#S00239F77-7924-42B6-9B10-4C1FD80BD423">PRECAUTIONS (Drug Interactions)</linkHtml> for
                                            discussion of hypotension with captopril therapy. </paragraph>
										<paragraph>Tachycardia, chest pain, and palpitations have
                                            each been observed in approximately 1 of 100 patients. </paragraph>
										<paragraph>Angina pectoris, myocardial infarction,
                                            Raynaud&#8217;s syndrome, and congestive heart
                                            failure have each occurred in 2 to 3 of 1000
                                        patients.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S7122F992-52D4-41D0-AC3B-09F989413CB8">
									<id root="69D4D6BA-C5E6-22AC-89A9-E3834FA13825"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Dysgeusia</title>
									<text>
										<paragraph>Approximately 2 to 4 (depending on renal status
                                            and dose) of 100 patients developed a diminution or loss
                                            of taste perception. Taste impairment is reversible and
                                            usually self-limited (2 to 3 months) even with continued
                                            drug administration. Weight loss may be associated with
                                            the loss of taste.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="SFA7D85AE-ACF6-4D95-BB12-32BD27D88AA7">
									<id root="FEA588D7-21CF-7031-6031-9DDD8F101C28"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Angioedema</title>
									<text>
										<paragraph>Angioedema involving the extremities, face, lips,
                                            mucous membranes, tongue, glottis or larynx has been
                                            reported in approximately one in 1000 patients.
                                            Angioedema involving the upper airways has caused fatal
                                            airway obstruction. (See&#160;<linkHtml href="#S68DA1A5D-5D69-4CCF-B8B1-2DF58A95B8B0">WARNINGS: Captopril: Angioedema</linkHtml> and<linkHtml href="#S6A71DAC9-C71E-45C3-BC01-87C0B1C3A85C">PRECAUTIONS: Information for
                                        Patients</linkHtml>).</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="SFC2C7ABA-9C19-440B-9EB7-E78F5FB5783E">
									<id root="9755A876-B927-73CA-3595-019E550804B3"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Cough</title>
									<text>
										<paragraph>Cough has been reported in 0.5 to 2 percent of
                                            patients treated with captopril in clinical trials (see<linkHtml href="#S5C30395E-04BA-4CA9-9CD7-5B1E1EB3EEAA">PRECAUTIONS: General, Captopril, Cough</linkHtml>).</paragraph>
										<paragraph>The following have been reported in about 0.5 to
                                            2 percent of patients but did not appear at increased
                                            frequency compared to placebo or other treatments used
                                            in controlled trials: gastric irritation, abdominal
                                            pain, nausea, vomiting, diarrhea, anorexia,
                                            constipation, aphthous ulcers, peptic ulcer, dizziness,
                                            headache, malaise, fatigue, insomnia, dry mouth,
                                            dyspnea, alopecia, paresthesias.</paragraph>
										<paragraph>Other clinical adverse effects reported since the
                                            drug was marketed are listed below by body system. In
                                            this setting, an incidence or causal relationship cannot                                be accurately determined.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S17AE7B55-8933-4341-8169-4D5C10879720">
									<id root="9E08BBA4-2721-72B3-D77D-D7E49C6E9182"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Body as a whole</title>
									<text>
										<paragraph>anaphylactoid reactions (see&#160;<linkHtml href="#S8C7DFCE0-2BF7-4BC5-B068-6F9B86C03341">WARNINGS: Captopril: Anaphylactoid and possibly
                                                related reactions</linkHtml> and <linkHtml href="#S896196D0-C248-48EF-9135-7938B0805E28">PRECAUTIONS: Hemodialysis</linkHtml>).</paragraph>
										<paragraph>General<br/>asthenia, gynecomastia.</paragraph>
										<paragraph>Cardiovascular<br/>cardiac arrest,
                                            cerebrovascular accident/insufficiency, rhythm
                                            disturbances, orthostatic hypotension, syncope. </paragraph>
										<paragraph>Dermatologic<br/>bullous pemphigus, erythema
                                            multiforme (including Stevens-Johnson syndrome),
                                            exfoliative dermatitis.</paragraph>
										<paragraph>Gastrointestinal</paragraph>
										<paragraph>pancreatitis, glossitis, dyspepsia.</paragraph>
										<paragraph>Hematologic</paragraph>
										<paragraph>anemia, including aplastic and hemolytic. </paragraph>
										<paragraph>Hepatobilliary</paragraph>
										<paragraph>jaundice, hepatitis, including rare cases of
                                            necrosis, cholestasis. </paragraph>
										<paragraph>Metabolic</paragraph>
										<paragraph>symptomatic hyponatremia. </paragraph>
										<paragraph>Musculoskeletal</paragraph>
										<paragraph>myalgia, myasthenia.</paragraph>
										<paragraph>Nervous/Psychiatric</paragraph>
										<paragraph>ataxia, confusion, depression, nervousness,
                                            somnolence. </paragraph>
										<paragraph>Respiratory</paragraph>
										<paragraph>bronchospasm, eosinophilic pneumonitis, rhinitis. </paragraph>
										<paragraph>Special Senses</paragraph>
										<paragraph>blurred vision. </paragraph>
										<paragraph>Urogenital</paragraph>
										<paragraph>impotence. </paragraph>
										<paragraph>As with other ACE inhibitors, a syndrome has been
                                            reported which may include: fever, myalgia, arthralgia,
                                            interstitial nephritis, vasculitis, rash or other
                                            dermatologic manifestations, eosinophilia and an
                                            elevated ESR.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="SFA348F17-E6C5-4A40-8E26-AE1910DE5275">
									<id root="192C87EC-FC7F-CECE-6D00-5F08024EE101"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Fetal/Neonatal Morbidity and Mortality</title>
									<text>
										<paragraph>
											<content styleCode="bold">See <linkHtml href="#SCC1D9261-A090-4EED-9B40-B8882FBEDA01">WARNINGS: Captopril, Fetal/Neonatal Morbidity
                                                  and Mortality</linkHtml>.</content>
										</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section ID="S2FF2DF24-186B-458B-991D-B60361D60FC1">
							<id root="16CE38A5-A7C6-5B8A-BC08-6E1A17194578"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
							<title mediaType="text/x-hl7-title+xml">Hydrochlorothiazide</title>
							<effectiveTime value="20060216"/>
							<component>
								<section ID="SF8E79D78-9350-4A19-8E03-11ECEFAAB9B8">
									<id root="9A61383C-3501-7DD5-6423-BAFADB40A071"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Gastrointestinal System</title>
									<text>
										<paragraph>anorexia, gastric irritation, nausea, vomiting,
                                            cramping, diarrhea, constipation, jaundice (intrahepatic
                                            cholestatic jaundice), pancreatitis, and
                                        sialadenitis.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S97806E26-2528-460C-8C82-3AD815B2F5A7">
									<id root="438FE209-03BA-E3AC-F26C-D385DDBE713C"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Central Nervous System</title>
									<text>
										<paragraph>dizziness, vertigo, paresthesias, headache, and
                                            xanthopsia.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S3D84ABB5-AB41-4542-8299-8631B830A8A5">
									<id root="9787F8FD-91C1-07D6-545C-07D6E30A5FDC"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Hematologic</title>
									<text>
										<paragraph>leukopenia, agranulocytosis, thrombocytopenia,
                                            aplastic anemia, and hemolytic anemia.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S87F858B0-19B7-47ED-8AF2-E62203BE1B4A">
									<id root="D1221EB5-0B58-A5D4-ED3F-79167B833ADA"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Cardiovascular</title>
									<text>
										<paragraph>orthostatic hypotension.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S39D4EC87-7238-43F0-9E1A-0039CB0AE26E">
									<id root="2865BBF1-4483-5F89-0119-0C1D0017E012"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Hypersensitivity</title>
									<text>
										<paragraph>purpura, photosensitivity, rash, urticaria,
                                            necrotizing angiitis (vasculitis; cutaneous vasculitis),
                                            fever, respiratory distress including pneumonitis, and
                                            anaphylactic reactions.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="SE7C10672-5C41-453B-B50B-69637CF9AF0E">
									<id root="F636AB73-88EA-D908-3697-4B6748673121"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Other</title>
									<text>
										<paragraph>hyperglycemia, glycosuria, hyperuricemia, muscle
                                            spasm, weakness, restlessness, and transient blurred
                                            vision.</paragraph>
										<paragraph>Whenever adverse reactions are moderate or                                 severe, thiazide dosage should be reduced or therapy
                                            withdrawn.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section ID="S61981536-EE69-4696-BBCE-56508AC9E9A2">
							<id root="2845F205-2B76-18C4-EB9F-4D3DB3CDAF50"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
							<title mediaType="text/x-hl7-title+xml">Altered Laboratory Findings</title>
							<effectiveTime value="20060216"/>
							<component>
								<section ID="S1924AD33-445F-4D3F-A765-33A21CC84196">
									<id root="7FB00321-A089-5385-F9B8-CFEA1FF50CDC"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Serum Electrolytes</title>
									<text>
										<paragraph>Hyperkalemia: small increases in serum potassium,
                                            especially in patients with renal impairment (see<linkHtml href="#SCAC058B4-2552-40F0-B123-938718E6484C">PRECAUTIONS: Captopril</linkHtml>).</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S150C3AE2-E4B6-4440-9CA6-33A77A302D8A">
									<id root="83C73A34-A70D-A4C0-EDCD-F8E15426CB8C"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Hyponatremia</title>
									<text>
										<paragraph>particularly in patients receiving a low sodium
                                            diet or concomitant diuretics.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S8E79E5FE-3D44-4E13-8425-AF0C650225CA">
									<id root="00ED583B-06D3-6B2D-EEBC-27B8D5927081"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">BUN/Serum Creatinine</title>
									<text>
										<paragraph>Transient elevations of BUN or serum creatinine
                                            especially in volume or salt depleted patients or those
                                            with renovascular hypertension may occur. Rapid
                                            reduction of longstanding or markedly elevated blood
                                            pressure can result in decreases in the glomerular
                                            filtration rate and, in turn, lead to increases in BUN
                                            or serum creatinine.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S40310EE0-5031-46C9-92A5-FFB2BB63A2C4">
									<id root="26CBAD68-B321-5D46-30FA-4942A7452045"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Hematologic</title>
									<text>
										<paragraph>A positive ANA has been reported.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
							<component>
								<section ID="S924D69CE-8629-4F89-81E5-11972B7BDE1A">
									<id root="B0CD8155-A6B5-1E18-20BC-992B7EB0F6BC"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
									<title mediaType="text/x-hl7-title+xml">Liver Function Tests</title>
									<text>
										<paragraph>Elevations of liver transaminases, alkaline                                 phosphatase, and serum bilirubin have
                                        occurred.</paragraph>
									</text>
									<effectiveTime value="20060216"/>
								</section>
							</component>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section ID="SEA8B61E2-23C1-475C-AA05-020E5082A6BF">
					<id root="3A438973-238D-6ED6-D036-21B5C34932CA"/>
					<code code="34088-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="OVERDOSAGE"/>
					<title mediaType="text/x-hl7-title+xml">OVERDOSAGE</title>
					<effectiveTime value="20060216"/>
					<component>
						<section ID="S1693548E-5ACF-4BA6-B94A-652A4BE62B04">
							<id root="51878C5C-BDBE-48C7-01ED-49970D06C532"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
							<title mediaType="text/x-hl7-title+xml">Captopril</title>
							<text>
								<paragraph>Correction of hypotension would be of primary concern.
                                    Volume expansion with an intravenous infusion of normal saline
                                    is the treatment of choice for restoration of blood pressure. </paragraph>
								<paragraph>While captopril may be removed from the adult circulation
                                    by hemodialysis, there is inadequate data concerning the
                                    effectiveness of hemodialysis for removing it from the
                                    circulation of neonates or children. Peritoneal dialysis is not
                                    effective for removing captopril; there is no information
                                    concerning exchange transfusion for removing captopril from the
                                    general circulation.</paragraph>
							</text>
							<effectiveTime value="20060216"/>
						</section>
					</component>
					<component>
						<section ID="S6C6CFA14-A41B-4E1A-9A56-8AF0EFD81184">
							<id root="5327DFB1-AB60-DC16-2B5A-D950027B0624"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
							<title mediaType="text/x-hl7-title+xml">Hydrochlorothiazide</title>
							<text>
								<paragraph>In addition to the expected diuresis, overdosage of
                                    thiazides may produce varying degrees of lethargy which may
                                    progress to coma within a few hours, with minimal depression of
                                    respiration and cardiovascular function and without evidence of
                                    serum electrolyte changes or dehydration. The mechanism of
                                    thiazide-induced CNS depression is unknown. Gastrointestinal
                                    irritation and hypermotility may occur. Transitory increase in
                                    BUN has been reported, and serum electrolyte changes may occur,
                                    especially in patients with impaired renal function. </paragraph>
								<paragraph>In addition to gastric lavage and supportive therapy for
                                    stupor or coma, symptomatic treatment of gastrointestinal
                                    effects may be needed. The degree to which hydrochlorothiazide
                                    is removed by hemodialysis has not been clearly established.
                                    Measures as required to maintain hydration, electrolyte balance,                   respiration, and cardiovascular and renal function should be
                                    instituted. </paragraph>
							</text>
							<effectiveTime value="20060216"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section ID="S752E7393-5D07-4A52-90E8-958DE89434A6">
					<id root="7D06879C-FA64-DC52-91C0-EECDD3A5B4AD"/>
					<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE &amp; ADMINISTRATION"/>
					<title mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
					<text>
						<paragraph>DOSAGE MUST BE INDIVIDUALIZED ACCORDING TO PATIENT&#8217;S
                            RESPONSE.</paragraph>
						<paragraph>Captopril and Hydrochlorothiazide tablets may be substituted for
                            the previously titrated individual components. </paragraph>
						<paragraph>Alternatively, therapy may be instituted with a single tablet of
                            Captopril and Hydrochlorothiazide 25 mg/15 mg taken once daily. For
                            patients insufficiently responsive to the initial dose, additional
                            captopril or hydrochlorothiazide may be added as individual components
                            or by using Captopril and Hydrochlorothiazide tablets 50 mg/15 mg, 25
                            mg/25 mg or 50 mg/25 mg, or divided doses may be used. </paragraph>
						<paragraph>Because the full effect of a given dose may not be attained for 6
                            to 8 weeks, dosage adjustments should generally be made at 6 week
                            intervals, unless the clinical situation demands more rapid adjustment.</paragraph>
						<paragraph>In general, daily doses of captopril should not exceed 150 mg and                   of hydrochlorothiazide should not exceed 50 mg. </paragraph>
						<paragraph>Captopril and Hydrochlorothiazide tablets should be taken one
                            hour before meals.</paragraph>
					</text>
					<effectiveTime value="20060216"/>
					<component>
						<section ID="S9145DACC-7633-4EF3-876A-21708694D22F">
							<id root="FD0D03BD-C213-24B3-D7CF-67A8727E2D41"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED"/>
							<title mediaType="text/x-hl7-title+xml">Dosage Adjustment in Renal Impairment</title>
							<text>
								<paragraph>Because captopril and hydrochlorothiazide are excreted
                                    primarily by the kidneys, excretion rates are reduced in
                                    patients with impaired renal function. These patients will take
                                    longer to reach steady-state captopril levels and will reach
                                    higher steady-state levels for a given daily dose than patients
                                    with normal renal function. Therefore, these patients may
                                    respond to smaller or less frequent doses of Captopril and
                                    Hydrochlorothiazide tablets. </paragraph>
								<paragraph>After the desired therapeutic effect has been achieved,
                                    the dose intervals should be increased or the total daily dose
                                    reduced until the minimal effective dose is achieved. When
                                    concomitant diuretic therapy is required in patients with severe
                                    renal impairment, a loop diuretic (e.g., furosemide), rather
                                    than a thiazide diuretic is preferred for use with captopril;
                                    therefore, for patients with severe renal dysfunction the
                                    captopril-hydrochlorothiazide combination tablet is not usually
                                    recommended (See&#160;<linkHtml href="#S3C3C19E7-BC88-4843-BA1A-40BC42D90435">WARNINGS:
                                        Captopril: Anaphylactoid reactions during membrane
                                    exposure</linkHtml> and <linkHtml href="#S896196D0-C248-48EF-9135-7938B0805E28">PRECAUTIONS:
                                        Hemodialysis</linkHtml>).</paragraph>
							</text>
							<effectiveTime value="20060216"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section ID="S1A7841E7-3C12-4E91-9E1A-FD96CD80C000">
					<id root="1804D495-BD4B-6878-925A-8BF06D997E91"/>
					<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED"/>
					<title mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
					<text>
						<paragraph>Captopril and Hydrochlorothiazide Tablets, USP are supplied as
                            follows:</paragraph>
						<paragraph>25 mg/15 mg &#8211; white, round tablets, debossed with&#8220;Endo&#8221; and &#8220;733&#8221; on one side and
                            quadrisected on the other.<br/>Bottles of
                            100&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NDC
                            60951-733-70<br/>25 mg/25 mg &#8211; peach, round tablets, debossed
                            with &#8220;Endo&#8221; and &#8220;741&#8221; on one
                            side and quadrisected on the other.<br/>Bottles of
                            100&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NDC
                            60951-741-70<br/>50 mg/15 mg &#8211; white, round tablets, debossed
                            with &#8220;Endo&#8221; and &#8220;739&#8221; on one
                            side and bisected on the other.<br/>Bottles of
                            100&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NDC
                            60951-739-70<br/>50 mg/25 mg &#8211; peach round tablets, debossed
                            with &#8220;Endo&#8221; and &#8220;731&#8221; on one
                            side and bisected on the other.<br/>Bottles of
                            100&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NDC
                            60951-731-70</paragraph>
						<paragraph>Store at controlled room temperature, 15&#176;-30&#176;C
                            (59&#176;-86&#176;F). Dispense in a tight container as defined
                            in the USP. Protect from moisture. Keep bottles tightly closed.</paragraph>
						<paragraph>
							<content styleCode="bold">Caution:</content> Federal (USA) law
                            prohibits dispensing without prescription.</paragraph>
						<paragraph>Manufactured for: <br/>
							<content styleCode="bold">Endo Pharmaceuticals Inc.</content>
							<br/>Chadds Ford, Pennsylvania 19317</paragraph>
						<paragraph>Manufactured by:<br/>DuPont Pharma<br/>Wilmington, Delaware 19880 </paragraph>
						<paragraph>6449-00/September, 1997</paragraph>
					</text>
					<effectiveTime value="20060216"/>
				</section>
			</component>
		</structuredBody>
	</component>
</document>
